Intestinal resection and reconstruction are crucial steps in surgical treatment for Crohn disease. However, anastomotic recurrence is a common complication following reconstruction surgery. Due to the complexity of the subsequent management of anastomotic recurrence, it has drawn increasing attention from specialists in inflammatory bowel disease. This article summarizes the risk factors of anastomotic recurrence after Crohn disease in order to provide references for clinical pracitice.

1.Roda G, Chien Ng S, Kotze PG, et al. Crohn's disease[J]. Nature Reviews Disease Primers, 2020,6(1):22.DOI: 10.1038/s41572-020-0156-2.

2.Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically  visualised ileal ulcers preceding symptoms[J]. Gut, 1992, 33(3): 331-335. DOI: 10.1136/gut.33.3.331.

3.Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease[J]. Gastroenterology, 1990, 99(4): 956-963.DOI: 10.1016/0016-5085(90)90613-6.

4.Torres J, Mehandru S, Colombel JF, et al. Crohn's disease[J]. Lancet, 2017, 389(10080): 1741-1755. DOI: 10.1016/S0140-6736(16)31711-1.

5.Hirten RP, Mashiana S, Cohen BL, et al. Ileocolic anastomotic inflammation after resection for Crohn's disease indicates  disease recurrence: a histopathologic study[J]. Scand J Gastroenterol, 2020, 55(7): 795-799.DOI: 10.1080/00365521.2020.1780305.

6.Petagna L, Antonelli A, Ganini C, et al. Pathophysiology of Crohn's disease inflammation and recurrence[J]. Biol Direct, 2020, 15(1): 23. DOI: 10.1186/s13062-020-00280-5.

7.Poredska K, Kunovsky L, Marek F, et al. The influence of microscopic inflammation at resection margins on early  postoperative endoscopic recurrence after ileocaecal resection for Crohn's disease[J]. J Crohns Colitis, 2020, 14(3): 361-368. DOI: 10.1093/ecco-jcc/jjz153.

8.Ha C, Martin A, Sepich-Poore GD, et al. Translocation of viable gut microbiota to mesenteric adipose drives formation of  creeping fat in humans[J]. Cell, 2020, 183(3): 666-683, e17. DOI: 10.1016/j.cell.2020.09.009.

9.Bortolotti P, Faure E, Kipnis E. Inflammasomes in tissue damages and immune disorders after trauma[J]. Front Immunol, 2018, 9: 1900. DOI: 10.3389/fimmu.2018.01900.

10.Caparrós E, Wiest R, Scharl M, et al. Dysbiotic microbiota interactions in Crohn's disease[J]. Gut Microbes, 2021, 13(1): 1949096. DOI: 10.1080/19490976.2021.1949096.

11.Baumgart DC, Sandborn WJ. Crohn's disease[J]. Lancet, 2012, 380(9853):1590-1605. DOI: 10.1016/S0140-6736(12)60026-9.

12.Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 pathway in Crohn's disease[J]. Front Immunol, 2021, 12: 622934. DOI: 10.3389/fimmu.2021.622934.

13.González S, Rodrigo L, Martínez-Borra J, et al. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha  production and inflammatory activity in Crohn's patients with fistulizing  disease[J]. Am J Gastroenterol, 2003, 98(5): 1101-1106. DOI: 10.1111/j.1572-0241.2003.07416.x.

14.Ihara S, Hirata Y, Koike K. TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium,  and the intestinal microbiota[J]. J Gastroenterol, 2017, 52(7): 777-787. DOI: 10.1007/s00535-017-1350-1.

15.Mudter J, Neurath MF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance[J]. Inflamm Bowel Dis, 2007, 13(8): 1016-1023.DOI: 10.1002/ibd.20148.

16.Khanna S, Raffals LE. The Microbiome in Crohn's disease: role in pathogenesis and role of microbiome replacement therapies[J]. Gastroenterol Clin North Am, 2017, 46(3): 481-492. DOI: 10.1016/j.gtc.2017.05.004.

17.Glassner KL, Abraham BP, Quigley E. The microbiome and inflammatory bowel disease[J]. J Allergy Clin Immunol, 2020, 145(1): 16-27.DOI: 10.1016/j.jaci.2019.11.003.

18.Morse BC, Simpson JP, Jones YR, et al. Determination of independent predictive factors for anastomotic leak: analysis of 682 intestinal anastomoses[J]. Am J Surg, 2013, 206(6): 950-955. DOI: 10.1016/j.amjsurg.2013.07.017.

19.Osborne MJ, Hudson M, Piasecki C, et al. Crohn's disease and anastomotic recurrence: microvascular ischaemia and  anastomotic healing in an animal model[J]. Br J Surg, 1993, 80(2): 226-229. DOI: 10.1002/bjs.1800800236.

20.Alshantti A, Hind D, Hancock L, et al. The role of Kono-S anastomosis and mesenteric resection in reducing recurrence after surgery for Crohn's disease: a systematic review[J]. Colorectal Dis, 2021, 23(1): 7-17. DOI: 10.1111/codi.15136.

21.Kono T, Ashida T, Ebisawa Y, et al. A new antimesenteric functional end-to-end handsewn anastomosis: surgical  prevention of anastomotic recurrence in Crohn's disease[J]. Dis Colon Rectum, 2011, 54(5): 586-592. DOI: 10.1007/DCR.0b013e318208b90f.

22.Kono T, Fichera A, Maeda K, et al. Kono-S anastomosis for surgical prophylaxis of anastomotic recurrence in Crohn's disease: an international multicenter study[J]. J Gastrointest Surg, 2016, 20(4): 783-790. DOI: 10.1007/s11605-015-3061-3.

23.Kelm M, Reibetanz J, Kim M, et al. Kono-S anastomosis in Crohn's disease: a retrospective study on postoperative  morbidity and disease recurrence in comparison to the conventional side-to-side anastomosis[J]. J Clin Med, 2022,11(23): 6915. DOI: 10.3390/jcm11236915.

24.Alshantti A, Hind D, Hancock L, et al. The role of Kono-S anastomosis and mesenteric resection in reducing recurrence  after surgery for Crohn's disease: a systematic review[J]. Colorectal Dis, 2021, 23(1): 7-17. DOI: 10.1111/codi.15136.

25.Fornaro R, Caristo G, Stratta E, et al. Crohn's disease and postoperative recurrence. The role of anastomotic  configurations and the kono-s anastomosis[J]. Ann Ital Chir, 2019, 90:111-120. https://pubmed.ncbi.nlm.nih.gov/31182693/.

26.Kann BR. Anastomotic considerations in Crohn's disease[J]. Clin Colon Rectal Surg, 2023, 36(1): 63-73. DOI: 10.1055/s-0042-1758770.

27.Telem DA, Chin EH, Nguyen SQ, et al. Risk factors for anastomotic leak following colorectal surgery: a case-control  study[J]. Arch Surg, 2010, 145(4): 371-376. DOI: 10.1001/archsurg.2010.40.

28.Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics[J]. Gastroenterology, 2013, 145(2): 293-308. DOI: 10.1053/j.gastro.2013.05.050.

29.Lees CW, Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and  natural history[J]. Expert Rev Gastroenterol Hepatol, 2009, 3(5): 513-534. DOI: 10.1586/egh.09.45.

30.Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics[J]. Gastroenterology, 2003, 124(7): 1767-1773. DOI: 10.1016/s0016-5085(03)00385-8.

31.Ngollo M, Perez K, Hammoudi N, et al. Identification of gene expression profiles associated with an increased risk of post-operative recurrence in Crohn's disease[J]. J Crohns Colitis, 2022, 16(8): 1269-1280. DOI: 10.1093/ecco-jcc/jjac021.

32.Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease[J]. Nature, 2007, 448(7152): 427-434. DOI: 10.1038/nature06005.

33.Liu JZ, Anderson CA. Genetic studies of Crohn's disease: past, present and future[J]. Best Pract Res Clin Gastroenterol, 2014, 28(3): 373-386. DOI: 10.1016/j.bpg.2014.04.009.

34.Gklavas A, Dellaportas D, Papaconstantinou I. Risk factors for postoperative recurrence of Crohn's disease with emphasis on surgical predictors[J]. Ann Gastroenterol, 2017, 30(6): 598-612. DOI: 10.20524/aog.2017.0195.

35.Bian D, Liu X, Wang C, et al. Association between dietary inflammatory index and sarcopenia in Crohn's disease patients[J]. Nutrients, 2022, 14(4). DOI: 10.3390/nu14040901.

36.Ashton JJ, Gavin J, Beattie RM. Exclusive enteral nutrition in Crohn's disease: evidence and practicalities[J]. Clin Nutr, 2019, 38(1): 80-89. DOI: 10.1016/j.clnu.2018.01.020.

37.Rozich JJ, Holmer A, Singh S. Effect of lifestyle factors on outcomes in patients with inflammatory bowel  diseases[J]. Am J Gastroenterol, 2020, 115(6): 832-840.DOI: 10.14309/ajg.0000000000000608.

38.Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of  observational studies[J]. Int J Colorectal Dis, 2008,23(12): 1213-1221. DOI: 10.1007/s00384-008-0542-9.

39.Liu TC, Kern JT, VanDussen KL, et al. Interaction between smoking and ATG16L1T300A triggers paneth cell defects in Crohn's disease[J]. J Clin Invest, 2018, 128(11): 5110-5122. DOI: 10.1172/JCI120453.

40.Lee S, Kuenzig ME, Ricciuto A, et al. Smoking may reduce the effectiveness of anti-TNF therapies to induce clinical  response and remission in Crohn's disease: a systematic review and Meta-analysis[J]. J Crohns Colitis, 2021, 15(1): 74-87. DOI: 10.1093/ecco-jcc/jjaa139.

41.Yamamoto T, Keighley MR. Smoking and disease recurrence after operation for Crohn's disease[J]. Br J Surg, 2000, 87(4): 398-404. DOI: 10.1046/j.1365-2168.2000.01443.x.